Please assess the completion status of the following clinical trial:

Trial Title: Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have newly diagnosed MM confirmed by the presence of bone marrow plasmacytosis with \> 10 percent plasma cells, sheets of plasma cells, or biopsy-proven plasmacytoma. Patients must have Durie-Salmon Stage IIA-B or IIIA-B. Patients with non-secretory myeloma are eligible. (These patients will not be included in the analysis of response rates, but will be assessed for toxicity and survival).~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2, or 3~* ≥ 18 years of age.~* Signed informed consent form~* Expected survival of greater than 8 weeks~* Capable of swallowing study medication tablets~* Capable of following directions regarding taking study medication, or has a daily care provider who will be responsible for administering study medication.~* Patients will be eligible for study even if they lack socioeconomic access to autologous transplantation. (These patients will be identified prior to randomization so as not to confound study results).~* All patients (in the event that they are randomized to the thalidomide/dexamethasone arm) must agree to take part in the System for Education and Prescribing Safety (S.T.E.P.S.)™. They must sign a separate informed consent for this program.~Exclusion Criteria:~* Elevated direct bilirubin \> 2 mg/dl~* Serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) \> 2 times the upper limit of normal (ULN)~* Absolute neutrophil count (ANC) \<1000/mL, unless felt to be secondary to myeloma~* Ongoing radiation therapy, or radiation therapy within 3 weeks prior to first treatment, unless the acute side effects associated with such therapy are resolved.~* Prior treatment for multiple myeloma~* Prior bisphosphonate use is allowed but they must be discontinued before starting treatment.~* Concurrent uncontrolled serious infection~* Patients with peripheral (sensory) neuropathy, grade 3 or higher~* Life-threatening illness (unrelated to tumor)~* History of any other ACTIVE and INVASIVE cancer other than the present condition (except non-melanoma skin cancer), unless in complete remission and off of all therapy for that disease for a minimum of 3 years.~* Women of childbearing potential (unless utilizing birth control) or who are pregnant or nursing will be excluded from this study.~* Patients with comorbid conditions that would contraindicate the use of vincristine, doxorubicin, dexamethasone, thalidomide, or zoledronate.~* Plasma Cell Leukemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VAD Treatment (Type: ACTIVE_COMPARATOR): VAD (vincristine, adriamycin, dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one cycle of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle.
- Thalidomide and Dexamethasone Treatment (Type: ACTIVE_COMPARATOR): Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4.

Based on this trial design, predict the completion outcome and termination type (if applicable).